S100P, widely known for its pro-cancer role across multiple cancer types, has also shown clinical relevance in triple negative breast cancer as its higher expression correlates with recurrence related events and higher metastasis in a cohort of 98 patients [74–76]. Here, S100P is linked to triple-negative breast carcinoma.